Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From William Masters
C-Suite Snippets: US Generics Industry Under Pressure
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
CNS Biomarkers: Monument Targets Schizophrenia, Anxiety And Cognitive Decline
Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.
Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.
C-Suite Snippets: Meindert Boyson's NICE Advice
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
Executive Briefing: C-Suite And Investors Discuss A New Decade
In Vivo held its first executive briefing in December 2019 focused on the outlook for the biopharma sector in the 2020s. Looking to the next decade, six panelists debated in front of an audience of invited guests a variety of issues expected to dominate agendas: pricing and reimbursement, digital transformation, mergers and acquisitions, funding and more.
Regenerative Medicines And Advanced Therapies: Progress, Problems And Promise
The Alliance for Regenerative Medicine’s Q3 report illustrates just how far the sector has come in the 10 years since the organization’s founding. The number of therapies in the pipeline has ballooned, in parallel with financing for development activities.